logo
Plus   Neg
Share
Email

Teradata Q4 Profit Beats Estimates - Quick Facts

Teradata Corp. (TDC), an analytic data platforms, applications and services company, reported fourth-quarter net income of $112 million, or $0.68 per share, compared to $112 million, or $0.66 per share, last year. Excluding stock-based compensation expense and special items, non-GAAP net income in the fourth quarter of 2013 was $144 million, or $0.88 per share.

On average, 26 analysts polled by Thomson Reuters expected the company to report profit per share of $0.85 for the quarter. Analysts' estimates typically exclude special items.

Revenue was $769 million, an increase of 4 percent from $740 million, a year ago. Revenue increased 5 percent year-over-year when compared in constant currency. Analysts expected revenue of $743.18 million for the quarter.

Teradata expects full-year 2014 revenue to grow approximately 3-7 percent in 2014, an increase of 4-8 percent when measured in constant currency. Teradata expects earnings per share for the full-year 2014 to be in the $2.39-$2.54 range on a GAAP basis and $2.85-$3.00 on a non-GAAP basis. Analysts expect the company to report fiscal 2014 earnings per share of $3.04.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
In the age of social media, it takes mere hours for a company to suffer the backlash of of allegations of racism. For some companies, these incidents have hurt their bottom line and sullied their reputations. For others, they were a blip caused by clumsy if not altogether coincidental missteps. In... BJ's Wholesale Club Holdings Inc., which is planning a return to the public market, has set terms for its planned initial public offering or IPO. In a filing with the U.S. Securities and Exchange Commission, the warehouse club operator said Monday that it plans to offer 37.5 million shares priced between $15 and $17 per share. At the top end of the range, the offering would raise $637.5 million. Shares of Valeant Pharmaceuticals International Inc. are falling more than 6 percent in Monday's trading following news that the U.S. Food and Drug Administration has failed to approve the Canada-based company's Duobrii lotion for the treatment of plaque psoriasis. Ortho Dermatologics, a division of Valeant Pharmaceuticals, said it has received a Complete Response Letter or CRL from the FDA.
Follow RTT